Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Residual Solvent Estimation by HPLC – V 2.0

Posted on By

Analytical Method Development: Residual Solvent Estimation by HPLC – V 2.0

SOP for Residual Solvent Estimation Using HPLC in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/080/2025
Supersedes SOP/AMD/080/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes the procedure for the development of an HPLC method for the estimation of residual solvents in active pharmaceutical ingredients (APIs) and drug products. The method aims

to identify and quantify Class 2 solvents as per ICH Q3C guidelines.

2. Scope

This procedure is applicable to the Analytical Method Development (AMD) department for the analysis of residual solvents in raw materials, APIs, intermediates, and finished dosage forms where gas chromatography (GC) is not feasible or practical.

3. Responsibilities

  • Analytical Chemist: Executes method development, prepares standard and test samples, performs injections, and evaluates results.
  • Reviewer: Reviews system suitability, linearity, detection limits, and confirms recovery accuracy.
  • QA Officer: Ensures documentation is complete and method complies with ICH Q3C and regulatory expectations.
  • Head – AMD: Reviews and approves the method for validation and routine analysis.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring the residual solvent method developed by HPLC is scientifically justified, validated, and suitable for regulatory filing.

See also  Analytical Method Development: SOP for Calibration of UV-Visible Spectrophotometer - V 2.0

5. Procedure

5.1 Pre-Development Considerations

  1. List likely residual solvents based on manufacturing history or ICH Q3C classification (Class 1, 2, 3).
  2. Assess solvent UV absorbance properties. HPLC estimation is suitable for UV-active or derivatized solvents.
  3. Document solvent list in Annexure-1: Solvent Risk Assessment Sheet.

5.2 HPLC Method Setup

  1. Column: C18, 250 mm × 4.6 mm, 5 µm
  2. Mobile Phase: Water:Acetonitrile (50:50) or buffer-based if necessary
  3. Detection: UV at 210–220 nm or refractive index detector if available
  4. Flow Rate: 1.0 mL/min
  5. Injection Volume: 20 µL
  6. Record in Annexure-2: HPLC Setup Log

5.3 Standard and Sample Preparation

  1. Standard: Prepare individual solvent solutions and a mixed standard at relevant ICH Q3C concentration limits (e.g., 5000 ppm for Class 2 solvents).
  2. Sample: Weigh suitable amount of API or formulation (e.g., 100 mg) and dissolve in diluent (water/MeOH or DMF).
  3. Filter all solutions with 0.45 µm filter and transfer to HPLC vials.
  4. Document in Annexure-3: Sample and Standard Preparation Log

5.4 System Suitability and Linearity

  1. Inject blank, individual solvents, mixed standard, and test samples.
  2. System Suitability:
    • RSD of replicate standard injections ≤ 2.0%
    • Resolution between closest eluting solvents ≥ 1.5
  3. Linearity range: LOQ to 120% of specification limit (e.g., 1000–6000 ppm).
  4. R² ≥ 0.999 required for each solvent.
  5. Record in Annexure-4: System Suitability and Linearity Log
See also  Analytical Method Development: Oxidation-Reduction Titration Development - V 2.0

5.5 Accuracy and Recovery

  1. Spike blank matrix with known solvent quantities at 50%, 100%, and 150% levels.
  2. Calculate % recovery:

    % Recovery = (Recovered Concentration / Spiked Concentration) × 100
  3. Acceptance criteria: 85%–115% recovery
  4. Document in Annexure-5: Recovery Study Summary

5.6 LOD and LOQ Determination

  1. Inject decreasing concentrations of solvent until S/N ≥ 3 (LOD) and ≥ 10 (LOQ) is achieved.
  2. Inject six replicates at LOQ level and ensure %RSD ≤ 10%
  3. Document in Annexure-6: LOD and LOQ Summary

5.7 Sample Analysis and Reporting

  1. Inject sample solution in duplicate.
  2. Quantify solvent content using calibration curve or response factor.
  3. Ensure results meet the ICH Q3C limits for respective solvents.
  4. Summarize results in Annexure-7: Residual Solvent Analysis Report

6. Abbreviations

  • HPLC: High-Performance Liquid Chromatography
  • LOD: Limit of Detection
  • LOQ: Limit of Quantification
  • ppm: Parts Per Million
  • SOP: Standard Operating Procedure

7. Documents

  1. Solvent Risk Assessment Sheet – Annexure-1
  2. HPLC Setup Log – Annexure-2
  3. Sample and Standard Preparation Log – Annexure-3
  4. System Suitability and Linearity Log – Annexure-4
  5. Recovery Study Summary – Annexure-5
  6. LOD and LOQ Summary – Annexure-6
  7. Residual Solvent Analysis Report – Annexure-7
See also  Analytical Method Development: Use of Design of Experiments (DoE) in Method Development - V 2.0

8. References

  • ICH Q3C (R8) – Impurities: Guideline for Residual Solvents
  • ICH Q2(R1) – Validation of Analytical Procedures
  • USP <467> – Residual Solvents
  • USP <621> – Chromatography

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Solvent Risk Assessment Sheet

Solvent Class Limit (ppm) Likely Source
Methanol Class 2 3000 API synthesis
Toluene Class 2 890 Crystallization

Annexure-2: HPLC Setup Log

Column Mobile Phase Detector λ Flow Rate
C18 Water:ACN (50:50) UV 210 nm 1.0 mL/min

Annexure-3: Sample and Standard Preparation Log

ID Type Concentration Diluent Prepared By
STD-Mix Standard 5000 ppm MeOH Rajesh Kumar

Annexure-4: System Suitability and Linearity Log

Parameter Observed Specification Status
RSD (n=5) 1.1% ≤ 2.0% Pass

Annexure-5: Recovery Study Summary

Spike Level Theoretical (ppm) Recovered (ppm) % Recovery
100% 5000 4962 99.2%

Annexure-6: LOD and LOQ Summary

Solvent LOD (ppm) LOQ (ppm) RSD @ LOQ
Toluene 5 15 6.8%

Annexure-7: Residual Solvent Analysis Report

Sample ID Solvent Result (ppm) Limit (ppm) Status
API-2025-01 Toluene 832 890 Complies

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included recovery, LOD/LOQ annexures and risk classification table Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for DO Cascade Settings in Bioreactor Operations – V 2.0
Next Post: BA-BE Studies: SOP for Bioanalytical Method Validation as per ICH M10 – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version